IBC Operating Procedures and Guidance
IBC Procedures
- Biological Research in Foreign Countries
- Biological Sharps Quick Reference Guide
- Biosafety Training Program Policy and Guidelines
- Campus Operations and Facilities Personnel Biosafety
- Collaborating: Policy for Animal Use and Biological Materials Activities with Collaborating Organizations
- Collaborating: Ceding Agreement Form
- Decommissioning of Laboratories
- Earphones in Biological Laboratories Guidance
- Guidance for Visitors/Non-Lab Personnel in University Biological Laboratories
- Guided Gene Drive Technology
- Institutional Biosafety Committee: Operating Policy and Procedures
- Isolation of Select Agent in a Non-Federal Certified UH Facility
- Minors in Laboratories
- Needles and Medical Sharps Handling and Disposal
- Needles: Reuse in Research Animals (under revision)
- UH IBC Policy for Tracking Research Protocol Approvals
- Service Animals in Facilities Overseen by UH IBC
- Styrofoam Dissecting Boards Guidance
- Synthetic Nucleic Acids and Nucleic Acid Synthesis Equipment- Framework for Screening
- UH Bio Waste Guidelines
- UH Biological Spill Plan
- Working Alone in Laboratories
Dual Use Research of Concern and Pathogens With Enhanced Pandemic Potential (DURC/PEPP)
For Researchers and Administrative Staff:
Research oversight is a critical component of effective biosafety and biosecurity practices and the responsible conduct of research involving biological agents and toxins. As part of ongoing updates and assessments of existing policies, the United States Government (USG) released the May 2024 DURC/PEPP Policy and associated Implementation Guidance, which supersedes the previous Federal DURC Policies. The new DURC/PEPP Policy defines and outlines oversight requirements for two categories of research at USG-funded institutions — “Category 1 research” involving dual use research of concern (DURC), and “Category 2 research” involving pathogens with enhanced pandemic potential (PEPP).
The DURC/PEPP Policy expands oversight of DURC to a wider scope of agents including all Select Agents and Toxins, all Risk Group 4 and most Risk Group 3 agents listed in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), and biological agents added during future updates to the DURC/PEPP Policy Implementation Guidance. There will be new oversight roles for researchers, applicants, recipients, and granting agencies. The DURC/PEPP Policy addresses the identification and mitigation of biosafety, biosecurity, and information risks associated with manipulation of certain pathogens that could cause significant harm to society, be it accidental or intentional. Updates reflect the evolving nature of scientific and technological risks.
General Expectations for Institutions and Researchers
Institutions, through their researchers, must assess their research at the proposal stage and continuously throughout the research life cycle for whether the research falls under the scope of Category 1 and/or Category 2 research as described in the DURC/PEPP Policy and Implementation Guidance. To assist with this, UH is providing links to general information about DURC/PEPP, as well as a PI Self-Assessment Tool, in the myGrant proposal questionnaire. Detailed training on DURC/PEPP is also available and highly recommended for researchers via the Collaborative Institutional Training Initiative (CITI Program). Those who have potential Category 1 or 2 research will be required to take this training.
For potential Category 1 or Category 2 research projects, once the applicant receives notification from the granting agency to provide supporting materials, the researcher must work with their Institutional Review Entity (IRE) to determine whether it meets the definition of Category 1 or Category 2. Researchers must also work with their IRE to develop a risk-benefit assessment and risk mitigation plan, as applicable, that must be approved by the granting agency before work can begin or continue.
Granting agencies will require institutional assessments of awards that are active at the time the policy goes into effect. The UH IBC and IRE will review new and ongoing research at UH to fulfill this institutional requirement of identifying potential DURC/PEPP projects. Researchers may receive a notification to complete a DURC/PEPP form in addition to his/her IBC registration form if the IBC deems that further review is needed to properly asses the project.
Please contact the UH IBC via email with any questions about this notice. Addition notices and clarification may be sent as they are received from federal agencies.
- UH Executive Policy 12.217, Dual Use Research of Concern and Pathogens With Enhanced Pandemic Potential, working policy currently under consultation
- DURC Executive Policy (2015 Version)
- UH Administrative Procedures 12.217, Dual Use Research of Concern and Pathogens With Enhanced Pandemic Potential, procedures currently under consultation
- DURC Administrative Procedures (2015 Version)
- PI Assessment Tool for Category 1 and/or Category 2 Research
Hawai‘i DLNR Regulations & Permits Policy
The state of Hawai‘i has regulations on the Collection and Possession of certain species or artifacts, Commercial Activity, Access to certain areas, and use of particular equipment for SCIENTIFIC, EDUCATIONAL OR PROPAGATION PURPOSES – HRS 187A-6. Any person with a bona fide scientific, educational or propagation purpose must apply in writing to obtain a Special Activity Permit to legally take certain specimens, use certain gear, and gain entrance into certain areas otherwise prohibited. Please consult Guidelines for Research, Collection, Possession, Commercial Activity, and Access Permits.
Inspections Procedures
All research, teaching, and testing facilities that store or use infectious agents or toxins must be inspected at least annually.
See “Forms and Templates” for Lab-specific Inspection Checklists.
Inventory (Laboratory) Procedures
A Laboratory Inventory Declaration (LID) of all biological agents and toxins must be completed annually and submitted to ORC.
“Biomaterials” include but are not limited to plants, animals, arthropods, invertebrates, insects, bacteria, viruses, parasites, fungi, oomycetes, mycoplasmas, RNA, recombinant DNA, prions, proteins, GMOs, cell lines [specify if transformed, immortalized], tissues (e.g., blood, lung), human specimens (sputum, urine, feces, tissue, swabs), non-human animal specimens, fetal calf serum, algae, protoclones and nematodes, weeds, biological control agents (including those not presently discovered or known to exist in Hawai‘i) and “new” microorganisms identified as those “combining genetic material from organisms in different genera.”
See “Forms and Templates” for Lab Declaration forms.
Biosafety Program Services for Non-UH Entities
U.S. Biological Safety Campaign
To better protect public health, the White House and NIH has urged us to review biosafety and biosecurity procedures, and to continue our sustained inventory monitoring. Take time to
- Clean out refrigerators and freezers, discard waste appropriately, and decontaminate
- Create or update an accurate inventory of infectious agents and biotoxins
- Update your biosafety training
- Contact ORC for assistance with any biosafety issues of concern
For further information:
Associations
- ABSA Risk Group Classification for Infectious Agents
- American Association for Microbiology (ASM)
- American Biological Safety Association (ABSA)
- European Molecular Biology Organization (EMBO)
- International Society for Infectious Diseases (ISID)
- ISID Program for Monitoring Emerging Diseases (ProMed)
Fact Sheets
- Biological Safety Officer (BSO)/Biological Safety Professional (BSP) Competency Fact Sheet
- BioSafety Levels (US)
- General Microbiology Fact Sheet
- Lentivirus Vector Fact Sheet
- OSHA
- Principles of Biosafety Fact Sheet
- Principles of Good Microbiological Practice Fact Sheet
- Select Agent Disease Fact Sheet
- Transgenic Animals and the Use of Recombinant DNA in Animals FAQ for Research Subjects to the NIH Guidelines
- Zoonotic Fact Sheet
Dengue in Hawai‘i
- Hawaiʻi State Department of Health: Dengue Information
- Center for Disease Control: Dengue Information
Mold Information
Federal Agencies
- Centers for Disease Control & Prevention (CDC) National Institute for Occupational Safety and Health (NIOSH)
- Environmental Protection Agency (EPA) – Laws, Regulations, Guidances
- EPA Approved Disinfectants
- FDA (Food and Drug Administration) – Vaccine, Blood, and Biologics Regulatory Information
- NIH (National Institutes of Health)
- NIH Office of Science Technology Policy
- NIH Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule
- OSHA-Bloodborne Pathogens and Needlestick Prevention Information
- US Department of Labor (DOL) Occupational Safety and Health Administration (OSHA)
Federal Regulations
- Code of Federal Regulations Search Engine
- Federal Register Search Engine
- National Select Agent Registry
- NIH rDNA Guidelines
- US DOT Pipeline and Hazardous Safety Administration
International
- Belgian Biosafety Server (European Biosafety Topics)
- CEN Laboratory Biorisk Management Standard
- European Biosafety Association
- Health and Safety Executive UK
- International Air Transport Association
- International Veterinary Biosafety Workgroup
- Office of Biosafety, LCDC (Canada)
- Public Health Agency of Canada Pathogen Safety Data Sheets and Risk Assessment (MSDS)
- WHO Laboratory BioSafety Manual
- World Health Organization (WHO)
Local Regulations
- DOH (Department of Health) West Nile Virus Information Center
- Hawaiʻi Department of Health (DOH)
- Guidance on Environmental Impact Statements (EIS) and Environmental Assessments (EAs)

